Search clinical trials for: Protein Kinase Inhibitors

Total 67403 results

M.D. Anderson Cancer Center

Withdrawn

A Phase 1a/1b Study to Determine the Recommended Phase 2 Dose, of Tepotinib in Participants With MET Alterations and Brain Tumors

Brain Tumor

United States
Polish Lymphoma Research Group
AstraZeneca

Active, not recruiting

Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT) (ACALLO)

Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Adverse Event | Chronic Graft-versus-host-disease | Response Rate

Poland
Centre Leon Berard

Active, not recruiting

Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase (TIPI)

Philadelphia Chromosome Positive CML | BCR-ABL Positive Chronic Myelogenous Leukemia

France
AbbVie

Completed

A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) With an Inadequate Response or Intolerance to Biologic DMARDs (SELECT-BEYOND)

Rheumatoid Arthritis

United States, Australia, Austria, Belgium, Canada, Czechia, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Korea, Republic of, Latvia, New Zealand, Poland, Portugal, Puerto Rico, Russian Federation, Slovakia, ... and more
AbbVie

Completed

A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

Ulcerative Colitis (UC)

United States, Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Canada, Chile, China, Colombia, Croatia, Czechia, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Japan, Korea,... and more
Sun Yat-sen University
Guangdong Provincial Hospital of Traditional Chinese Medicine; Guangdong Provincial...

Active, not recruiting

PD-1 Inhibitors Combined With VEGF Inhibitors for Locally Advanced dMMR/MSI-H Colorectal Cancer

Colorectal Cancer | Microsatellite Instability High

China
National Cancer Center, China

Not yet recruiting

A Study With BPI-1178 and Osimertinib in Advanced Non-small Cell Lung Cancer Patients With EGFR Mutations (EGFR)

NSCLC
Medical College of Wisconsin

Not yet recruiting

LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies

Follicular Lymphoma | Burkitt Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma
AstraZeneca

Recruiting

A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC) (TARGET)

Stage II-IIIB Non-small Cell Lung Carcinoma

Spain, Korea, Republic of, Philippines, Italy, United States, Malaysia, Taiwan, Thailand, Hong Kong, United Kingdom, Singapore
Georgetown University
AbbVie; Pharmacyclics LLC.; Hackensack Meridian Health

Active, not recruiting

Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

Relapsed Follicular Lymphoma | Refractory Follicular Lymphoma

United States
Hyo Song Kim

Completed

A Study to Evaluate the Safety and Efficacy of Vactosertib and Imatinib in Patients With Advanced Desmoid Tumor

Desmoid Tumor

Korea, Republic of
National Cancer Institute (NCI)

Completed

Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib

Lung Neoplasms | Lung Adenocarcinoma

United States
Jennifer R. Brown, MD, PhD
AstraZeneca; TG Therapeutics, Inc.

Active, not recruiting

Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL

Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | Relapsed Chronic Lymphocytic Leukemia

United States
AbbVie

Active, not recruiting

A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)

Atopic Dermatitis

United States, Australia, Austria, Belgium, Bulgaria, Canada, Croatia, Czechia, Denmark, France, Germany, Greece, Hungary, Ireland, Italy, Korea, Republic of, Netherlands, New Zealand, Portugal, Singapore, Spain, Taiwan, United Kingdom
AbbVie

Completed

A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy

Crohn's Disease

United States, Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, Estonia, France, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy and more
Xspray Pharma AB
Axis Clinicals Limited

Completed

Evaluating the Effects of Omeprazole on the Pharmacokinetics of XS004 (Dasatinib) Tablets in Healthy Adult Subjects Under Fasting Conditions

Pharmacokinetics | Drug Interactions

United States
Fox Chase Cancer Center
Millennium Pharmaceuticals, Inc.

Terminated

Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Recurrent

United States
Tang-Du Hospital

Recruiting

An Observational Study of Furmonertinib for EGFR Mutation-positive NSCLC Patients With Brain Metastasis

EGF-R Positive Non-Small Cell Lung Cancer | CNS Metastases

China
Helwan University

Not yet recruiting

Palbociclib in Metastatic Breast Cancer: Gene Polymorphism-based Study in Egyptian Patients. (Palbociclib)

Metastatic Breast Cancer | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Hormone-receptor-positive Breast Cancer
Bristol-Myers Squibb

Not yet recruiting

Real-World Safety and Effectiveness of Sotyktu (Deucravacitinib) in Patients With Moderate-to-Severe Plaque Psoriasis in Korea

Moderate-to-severe Plaque Psoriasis

Korea, Republic of
Juan LI, MD

Recruiting

To Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy

Non Small Cell Lung Cancer | EGFR Exon 20 Insertion Mutation

China
Pusan National University Hospital
Yuhan Corporation

Not yet recruiting

Impact of Lazertinib Dose Modification on Effectiveness and Safety

Non-small Cell Lung Cancer

Korea, Republic of
Huashan Hospital
Boehringer Ingelheim

Not yet recruiting

Study to Evaluate the Efficacy of Afatinib in Skull Base Chordoma

Chordoma of Clivus

China
Shanghai JMT-Bio Inc.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer

Locally Advanced or Metastatic Non-Small Cell Lung Cancer | EGFR Exon20 Insertion Mutations

China
Yonsei University

Recruiting

A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Neoadjuvant Osimertinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harbouring EGFR Mutations

Non Small Cell Lung Cancer

Korea, Republic of
Jun Zhang, MD, PhD
University of Iowa; University of Kentucky

Recruiting

Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy (Ipat-Lung)

NSCLC Stage IV | NSCLC Stage IIIB

United States
Shenzhen Second People's Hospital

Recruiting

Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP

Chronic Myeloid Leukemia | Dasatinib | BCR-ABL

China
Fundación Teófilo Hernando, Spain

Recruiting

Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Chronic Myeloid Leukemia

Chronic Myeloid Leukemia

Spain
University Hospital, Basel, Switzerland

Recruiting

Nintedanib in Patients With Bronchiolitis Obliterans Syndrome Following Hematopoietic Stem Cell Transplantation (NINBOST2018)

Bronchiolitis Obliterans Syndrome (BOS) | Bronchiolitis Obliterans (BO)

Switzerland, Saudi Arabia
Canadian Cancer Trials Group
Pfizer

Active, not recruiting

Palbociclib in Patients With Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer

Canada
Intergroupe Francophone de Cancerologie Thoracique

Active, not recruiting

Study of Osimertinib in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation (ORBITAL)

Non Small Cell Lung Cancer Metastatic | Brain Metastases | EGFR Activating Mutation | Leptomeningeal Metastasis

France
Pfizer

Completed

UK Ibrance Patient Program (IPP) Study (ROIS)

HR+/HER2- Locally Advanced, Metastatic Breast Cancer

United Kingdom
Shanghai Pulmonary Hospital, Shanghai, China

Completed

Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma

EGFR Gene Mutation | Lung Adenocarcinoma Stage III

China
Shanghai Zhongshan Hospital

Completed

Effect of Tofacitinib in Treating ANCA-associated Vasculitis

Drug Use | ANCA Associated Vasculitis | JAK-STAT Pathway Deregulation

China
Asan Medical Center
AstraZeneca

Completed

TAGRISSO (Osimertinib) in NSCLC Patients in Whom T790 Mutations Are Detected by Liquid Biopsy

NSCLC

Korea, Republic of
Washington University School of Medicine

Active, not recruiting

Tofacitinib for Inflammatory Eye Disease

Uveitis | Scleritis

United States
Memorial Sloan Kettering Cancer Center

Completed

Nintedanib in Patients With Advanced Esophagogastric Cancer

Esophagogastric Adenocarcinoma

United States
Boehringer Ingelheim

Completed

Afatinib Monotherapy in Patients With ERBB-deregulated Metastatic Urothelial Tract Carcinoma After Failure of Platinum Based Chemotherapy (LUX-Bladder 1)

Urologic Neoplasms

Spain, France, Italy
Sun Yat-sen University

Withdrawn

Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma

China
Boehringer Ingelheim

Completed

Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older

Carcinoma, Non-Small-Cell Lung | ErbB Receptors

United States
Nanfang Hospital of Southern Medical University
Xiangya Hospital of Central South University; Peking University People's Hospital and other collaborators

Completed

Sorafenib for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3-ITD Positive AML

Acute Myeloid Leukemia | Hematopoietic Stem Cell Transplantation

China
Sun Yat-sen University

Unknown

The Impact on Recurrence Risk of Adjuvant Lenvatinib for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.

Hepatocellular Carcinoma

China
Boehringer Ingelheim

Completed

Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation

Carcinoma, Non-Small-Cell Lung

Hong Kong, China, Taiwan, Singapore, India
Hoffmann-La Roche

No longer available

Expanded Access to RXDX-105 for Cancers With RET Alterations

Cancers With RET Alterations

United States
Hoffmann-La Roche

No longer available

Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene Fusions

Cancers With NTRK, ROS1, or ALK Gene Fusions

United States
Stanford University

Completed

Tofacitinib for the Treatment of Alopecia Areata and Its Variants

Alopecia Areata | Alopecia Totalis | Alopecia Universalis

United States
Pfizer

Completed

Safety and Pharmacokinetic Study of PF-06700841 in Japanese Healthy Volunteers

Healthy

Belgium
Zhejiang Cancer Hospital

Unknown

Apatinib in Treating Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)

Nasopharyngeal Carcinoma

China
Weill Medical College of Cornell University
Bristol-Myers Squibb

Terminated

Dasatinib in Polycythemia Vera

Polycythemia Vera

United States
Henan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Apatinib Treatment for Advanced Esophagus Cancer

Advanced Esophagus Cancer

China

Search clinical trials for: Protein Kinase Inhibitors

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Thailand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations